|Bid||1.5100 x 3100|
|Ask||1.5200 x 21500|
|Day's Range||1.5100 - 1.5515|
|52 Week Range||1.4800 - 6.7500|
|Beta (5Y Monthly)||3.99|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 23, 2023 - Feb 27, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.33|
Even though many stocks have fallen sharply in price, not all are bargains -- investors must remains selective.
Like meme stocks will do from time to time, Ocugen (NASDAQ: OCGN) on Wednesday saw a notable price drop a day after a surge. The company was hit by quite a severe price target cut from an analyst, a move that ruined the party after Tuesday's post-earnings run-up. Before market open Wednesday, Noble Capital's Robert LeBoyer made a nearly 40% chop to his Ocugen target.
A third-quarter report, complete with clinical updates, is more than enough to satisfy the biotech's bulls.